Endocrinological studies with (7 alpha, 17 alpha)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (Org OD 14).
A novel steroid, (7 alpha, 17 alpha)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (Org OD 14), is described which has concomitant weak estrogenic, progestational and androgenic activities. This hormonal profile was demonstrated using various endocrinological tests and the results were evaluated in terms of well-known reference compounds. It has been well established that combinations of estrogens, androgens and progestagens exert positive or synergistic effects on certain target organs, e.g. the hypothalamic-pituitary axis, and antagonistic or complementary effects on others, e.g. on the endometrium. Org OD 14 with estrogenic, androgenic and progestational activities can therefore be expected to induce complex effects on various target organs. This explains the observed effects of the compound on hypothalamic-pituitary axis, bone-loss, endometrium and sexual behaviour.
D045930:Anabolic Agents / Q000494:pharmacology*; D000728:Androgens / Q000378:metabolism; D000818:Animals; D001842:Bone and Bones / Q000187:drug effects; D002369:Castration; D004702:Endocrine Glands / Q000187:drug effects*; D004717:Endometrium / Q000187:drug effects; D004848:Epithelium / Q000187:drug effects; D004965:Estrogen Antagonists; D005260:Female; D005298:Fertility / Q000187:drug effects; D008297:Male; D008901:Mineralocorticoids; D009652:Norpregnenes / Q000494:pharmacology*; D009929:Organ Size / Q000187:drug effects; D010902:Pituitary Gland / Q000378:metabolism; D011817:Rabbits; D051381:Rats; D011919:Rats, Inbred Strains; D012726:Sexual Behavior, Animal / Q000187:drug effects; D014599:Uterus / Q000187:drug effects; D014621:Vagina / Q000187:drug effects
D045930:Anabolic Agents; D000728:Androgens; D004965:Estrogen Antagonists; D008901:Mineralocorticoids; D009652:Norpregnenes; C027385:tibolone